Evidence · Sources read August 16, 2026
Does HRT help with weight loss? Mostly no, and the trial numbers say why
The best randomized result we found for hormone therapy and weight is a trial that measured less weight gain, and never measured a loss.
Mostly no. Hormone therapy is not a weight-loss treatment, and the estradiol label we read for this page lists 6 indications with weight on none of them. The Cochrane review of 22 randomized trials found a mean weight-gain difference of 0.66 kg between estrogen alone and no hormone therapy (95% CI -0.62 to 1.93), and -0.47 kg for estrogen plus progestogen (95% CI -1.63 to 0.69). Both intervals cross zero. The most favorable randomized result we found, PEPI, has women on estrogen gaining 1.0 kg less over three years than women on placebo. The trial reported that as reduced weight gain, never as weight loss. What the transition genuinely changes is where the fat sits: in SWAN, visceral fat rose 6.24 percent a year through the transition while the rate of weight gain did not accelerate at all.
By Iacob Pastina. Every figure below was read from a primary source on August 16, 2026: the published trials on PubMed, the prescribing information on DailyMed, and the federal activity guideline on the document it is published in. Effect sizes are rendered with their comparator and their confidence interval or p value every time, because this is the topic where dropping the comparator turns a null result into a sales claim.
This is general information, not medical advice. Hormone therapy is a prescription treatment with real benefits and real risks, and neither this page nor any page decides it for you. Whether it is right for you is a decision for you and a licensed clinician.
Does HRT help with weight loss?
Hormone therapy is a prescription treatment for the symptoms of estrogen loss: vasomotor symptoms, the genitourinary syndrome of menopause, and postmenopausal bone loss. It replaces the estrogen the ovary stopped producing, which is why it acts on the symptoms of that loss, and the randomized record on body weight runs from no measurable difference against placebo to, at its most favorable, one kilogram less weight gained across three years. Midlife weight gain and the menopause transition are two different things: the transition changes where fat sits and how much lean tissue a woman carries, while the rate at which the scale climbs does not change when it begins.
An indication list is the complete set of things a drug is approved to treat, and prescribing a drug outside that list does not create the evidence that would justify it. The label for estradiol tablets, read for this page on 2026-08-16, lists 6 indications and weight is on none of them; the only place that label treats weight as something the drug might change is in adverse reactions, as “Increase or decrease in weight”, in both directions. What hormone therapy is and is not indicated for.
Does menopause cause weight gain?
The SWAN cohort measured this with dual energy x-ray absorptiometry rather than a scale, and the two instruments give different answers. At the start of the menopause transition the rate of fat gain doubled and lean mass declined, and the gains and losses continued until two years after the final menstrual period. After that the trajectories of fat and lean mass decelerated to zero slope. Meanwhile, weight climbed linearly during premenopause without acceleration at the menopause transition, and its trajectory became flat after it.
The authors' own conclusion
Accelerated gains in fat mass and losses of lean mass are transition-related phenomena. The rate of increase in the sum of fat mass and lean mass does not differ between premenopause and the transition, so there is no discernable change in the rate of weight gain at the start of the transition. PMID 30843880
Read that carefully, because it cuts both ways and both cuts are worth having. Midlife weight gain is real and the women reporting it are not imagining it. What SWAN found is that the transition itself is not the accelerant on the scale. Fat gain doubled and lean mass fell, and the two moved in opposite directions by roughly enough to leave the total climbing at the pace it had been climbing already. A woman who steps on a scale, sees the same slow rise she saw at 43, and concludes nothing changed at 51 is reading a real number off an instrument that cannot measure the thing that changed.
A smaller study measured the machinery underneath. It followed 156 women (103 White and 53 African-American women, all premenopausal at entry) for 4 years, 51 of whom became postmenopausal in that window. All the women gained subcutaneous abdominal fat over the four years. Only the women who became postmenopausal had a significant increase in visceral fat. A subset of 34 women spent 24 hours in a whole-room calorimeter at baseline and again at year four: Twenty-four hour and sleeping energy expenditure decreased significantly with age; however, the decrease in sleeping energy expenditure was 1.5-fold greater in women who became postmenopausal compared with premenopausal controls (-7.9 versus -5.3 percent). Fat oxidation decreased by 32 percent in women who became postmenopausal (P < 0.05), but did not change in those who remained premenopausal. Their conclusion: menopause onset is associated with decreased energy expenditure and fat oxidation that can predispose to obesity if lifestyle changes are not made.
Hold the sample sizes in view. The calorimeter arm is 34 women, which is small enough that the percentages should be read as a direction rather than a measurement you can plan around. PMID 18332882. The same paper also reports that physical activity decreased significantly two years before menopause and remained low. That one is worth sitting with, because it is the input a woman controls.
Why does menopause cause belly fat?
Because the fat moves toward the trunk, and SWAN measured how fast in 380 women scanned over a median 11.8 years, 1996 to 2013. Every rate below is an annualized percent change and every one is reported as statistically non-zero.
| Measure | Premenopause | Through the transition | Postmenopause |
|---|---|---|---|
| Visceral fat (DXA) | Began increasing at the transition | 6.24% / yr | 1.47% / yr |
| Android fat, the trunk depot (DXA) | 1.21% / yr | 5.54% / yr | 0.9% / yr |
| Gynoid fat, the hip and thigh depot (DXA) | Began increasing at the transition | 2.03% / yr | -0.87% / yr |
| Waist circumference (tape) | 0.55% / yr | 0.96% / yr | 0.55% / yr |
| Hip circumference (tape) | 0.2% / yr | 0.35% / yr | Decelerated to zero slope |
Rates as published in the SWAN regional-fat analysis, PMID 34061966. Mean baseline age 45.7, cohort composition 16 percent Black, 41 percent Japanese, 43 percent White. The rates below are for the White referent. The paper reports statistically significant differences in some trajectories in Black and Japanese women.
Why the tape measure disagrees with the mirror
The three waist rates are all statistically non-zero and the paper reports that they are not statistically different from each other. The same is true of the two hip rates. Fat moved; the tape did not register the move.The paper's own conclusion says it plainly: “The menopause transition is associated with the development of central adiposity. Waist or hip circumferences are less sensitive to changes in fat distribution.”
So a woman whose waist measurement has barely moved while her shape clearly has is not misremembering. Visceral fat at 6.24 percent a year and android fat at 5.54 percent a year sit behind a waist growing under one percent a year, and the tape cannot separate a centimetre of visceral fat from a centimetre of anything else.
What hormone therapy does to weight: the randomized record
Below is every randomized result we could find on hormone therapy and body weight or body composition, each with its comparator and its interval or p value. Three sources, and they do not fully agree. The meta-analysis found no statistically significant weight difference in either direction; PEPI, a three-year randomized trial in 875 women, found a significant one of a kilogram. Both readings are below with their numbers attached, because flattening them into one answer is how this topic goes wrong. Nothing here is cherry-picked toward the negative answer, which is worth saying plainly because the negative answer is the one that costs this site money.
Systematic review and meta-analysis of randomized, placebo or no-treatment controlled trials. 22 trials met the inclusion criteria; the reviewers report that one of them was not available in a form that allowed it into the meta-analysis, and that a further 24 trials were awaiting assessment. Perimenopausal and postmenopausal women.
Body weight, unopposed oestrogen against no hormone therapy: Weighted mean difference 0.66 kg (95% CI -0.62 to 1.93). The interval crosses zero, so no statistically significant difference was found.
Same review, combined regimen arm. Perimenopausal and postmenopausal women.
Body weight, oestrogen plus progestogen against no hormone therapy: Weighted mean difference -0.47 kg (95% CI -1.63 to 0.69). The interval crosses zero, so no statistically significant difference was found.
Same review, body mass index. Perimenopausal and postmenopausal women.
BMI, oestrogen plus progestogen against no hormone therapy: Weighted mean difference -0.50 (95% CI -1.06 to 0.06). The interval crosses zero. The reviewers report insufficient data to meta-analyse waist-hip ratio, fat mass or skinfold thickness at all.
Three-year placebo-controlled randomized trial of four hormone regimens, all built on conjugated equine estrogens 0.625 mg daily. 875 postmenopausal women.
Body weight at three years: Women assigned to estrogen with or without a progestogen averaged 1.0 kg LESS weight gain than women assigned to placebo (P = 0.006). The trial reported this as reduced weight gain and reported no weight loss in any arm. There were no significant differences among the four active regimens.
Same trial, girth outcomes. 875 postmenopausal women.
Waist and hip circumference at three years: 1.2 cm less increase in waist girth (P = 0.01) and 0.3 cm less increase in hip girth (P = 0.07). In regression models that included weight change as a covariate, none of these differences reached statistical significance.
Three-year randomized placebo-controlled substudy, DXA. 835 women, 437 on estrogen plus progestin and 398 on placebo, mean age 63.1 and on average 13.8 years past menopause.
Lean soft tissue mass and the ratio of trunk to leg fat: The treated women lost less lean soft tissue mass (-0.04 kg) than the placebo group (-0.44 kg, P = 0.001), and their trunk-to-leg fat ratio moved -0.025 against 0.004 on placebo (P = 0.003). The authors write that the effect sizes were small and that whether these changes lead to significant health benefits remains to be confirmed.
The Cochrane reviewers wrote the summary sentence themselves: “There is evidence of no effect of unopposed oestrogen or combined oestrogen on body weight, indicating that these regimens do not cause extra weight gain in addition to that normally gained at menopause.” Their consumer summary goes one step further and closes the door on the optimistic reading too: “The review of trials found no evidence that unopposed oestrogen and combined oestrogen and progestogen have an effect on body weight additional to that usually gained at the time of menopause. The review did not find any evidence that HRT prevents weight gain experienced at menopause.”
This review is old and its age belongs on the page. Its own record on cochrane.org carried no withdrawal, out-of-date or supersession notice when we checked it on August 16, 2026, and we found no newer systematic review putting a different number on the same question. Read the two randomized trials below alongside it rather than instead of it. It was published 24 January 2000, and its own reviewers reported insufficient data to meta-analyse waist-hip ratio, fat mass or skinfold thickness at all, so the fat-distribution question is answered by the two individual trials above rather than by the pooled estimate. The plain language summary, on cochrane.org.
What PEPI's one kilogram is actually worth
It is the number every optimistic page is standing on, so it deserves arithmetic. 1.0 kg across 3 years is about 0.33 kg a year, calculated by us rather than reported by the trial. It is avoided gain rather than loss: the trial reported reduced weight gain and reported no weight loss in any arm. And the waist result, 1.2 cm less increase, stopped being statistically significant once the model controlled for weight change, which means the girth finding was mostly the weight finding wearing a different hat.
1.0 kg divided by three years, calculated by us. PEPI reported a three-year endpoint and did not publish an annual rate, so this is arithmetic on their number rather than a finding of theirs.
The one place hormone therapy did move something
The WHI body composition substudy found the treated women lost less lean soft tissue over three years than the placebo group, 0.04 kg against 0.44 kg, and shifted the trunk-to-leg fat ratio slightly away from the trunk. That maps onto exactly what SWAN says the transition takes, which makes it the most biologically coherent result in the set. It is also the result whose own authors wrote that the effect sizes were small and that whether these changes lead to significant health benefits remains to be confirmed. The gap between the two arms works out to four tenths of a kilogram of lean tissue over three years, our subtraction on their two figures rather than a number the paper printed. A real difference and a small one, and a body composition finding rather than a weight finding.
What the label says, and what the guideline says
A label is the shortest route to this answer, because the indication list is the complete set of things a drug is approved to treat. The prescribing information for Estradiol tablets, USP, SPL effective 2026-07-01 and read from the structured XML on 2026-08-16, lists 6 indications:
- 1.Treatment of moderate to severe vasomotor symptoms associated with the menopause
- 2.Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause
- 3.Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure
- 4.Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease
- 5.Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only)
- 6.Prevention of osteoporosis
Weight is absent from that list. The only place on the whole label where weight is treated as something the drug might change is ADVERSE REACTIONS, item 8, Miscellaneous, where the entry reads “Increase or decrease in weight”. Both directions, in the adverse reactions column. The word weight appears three other times on this label and none of them describes something the drug does. Twice it is weight-bearing exercise recommended for bone, once in the osteoporosis indication and once in the patient leaflet, and once it is being overweight named as a cardiac risk factor in the patient leaflet. This label lists its adverse reactions by body system with no frequency attached to any of them and no placebo comparison, so it publishes no rate for weight change in either direction. Read the label.
What the guideline body says it is effective for
“Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture.”
Three things on that list, and weight is not one of them. The statement makes no weight claim in either direction, and reading a claim into that silence would be the same error as reading one out of it. PMID 35797481
For the opposite question, whether hormone therapy makes you gain, the patch label publishes rates by dose and they have no dose-response. That table, with arm sizes and the placebo column, sits on the side effects page rather than here.
Can HRT help with weight loss indirectly?
This is the honest version of the yes, and it deserves a fair hearing before it gets its limits drawn. The argument runs: treating hot flashes and night sweats fixes sleep, better sleep protects the machinery that governs appetite and how a body spends a calorie deficit, and a woman who is sleeping and moving again does better on her own terms. Both halves of that chain have evidence behind them.
Hormone therapy on sleep
Sleep complaints are reported by 40 to 60 percent of menopausal women, and poor sleep is a risk factor for cardiovascular disease, diabetes and obesity. A meta-analysis pooling seven trials covering 15,468 women found a standardized mean difference of -0.54 (95% CI -0.91 to -0.18), which the authors graded as moderate quality evidence. The effect was found in women who had vasomotor symptoms at baseline. No difference was noted when women without such symptoms were analysed separately, or when the two groups were combined. The pooled trials were at a moderate to high risk of bias. PMID 27515805
Sleep on what a deficit costs you
Randomized two-period two-condition crossover: 14 days of moderate caloric restriction with either 8.5 or 5.5 hours of nighttime sleep opportunity, in 10 overweight adults, 3 women and 7 men, mean age 41 and mean BMI 27.4. Sleep curtailment decreased the proportion of weight lost as fat by 55 percent (1.4 versus 0.6 kg, P = 0.043) and increased the loss of fat-free body mass by 60 percent (1.5 versus 2.4 kg, P = 0.002). The authors name the limitation themselves: the nature of the study limited its duration and sample size. Three of the ten participants were women and none of them were described as menopausal, so this is a mechanism worth knowing rather than a result measured in the women this page is written for. PMID 20921542
The link in the chain nobody has measured
No randomized trial has tested whether treating vasomotor symptoms with hormone therapy produces weight loss through better sleep. The two halves of that chain are each supported and the chain itself has never been measured end to end. Anyone telling you the size of that effect is telling you a number that does not exist.
Which leaves the indirect route as a plausible mechanism with an unmeasured size. Worth knowing, and worth refusing to quantify. If a provider quotes you a figure for how much weight hormone therapy will take off through better sleep, ask which trial produced it. There is not one.
Does your HRT provider also sell a weight-loss product?
Worth checking, because it changes how a page answering this question should be read. Of the 13women's-wing platforms we track, 3 run a weight-loss or weight-management line on the same site according to our own provider records, and 10 carry no such line in anything we have documented.
- Gala Health7.2/10Transparency C$86/mo
- Gennev7.1/10Transparency B$199 per visit
- Telos RX6.9/10Transparency DNot published
Read 3 as a floor rather than a census. We grade these platforms on their hormone line, so a weight product enters our records only when it turned up during hormone research. We have not audited the remaining 10for one. This is a disclosure rather than an accusation: selling two things is legal, common and often convenient for the patient. It is worth knowing when you are reading that company's answer to the question at the top of this page.
Our own position, for the same reason: this site covers menopause hormone therapy and testosterone therapy. It does not cover, rank, recommend or take commission on any weight-loss medicine, which is why the answer above could be written without checking what it costs us. How featuring works here and the scoring rubric.
What actually works for menopause weight gain
Four things follow from the evidence above rather than from anybody's program. Only the last of them involves a prescription, and even that one is prescribed for the symptom rather than for the weight.
1. Change the instrument
SWAN found the rate of weight gain unchanged at the transition while fat and lean mass moved in opposite directions, and found waist circumference growing at a rate statistically indistinguishable from its premenopausal rate while visceral fat rose 6.24 percent a year. Both of the instruments most women use are blind to the change they are trying to track. Body composition is what moved, so a DXA scan, or at minimum a consistent set of photographs and how clothes fit, tells you more than the number the scale gives you on a Tuesday.
2. Defend the lean mass, deliberately
Lean mass is the tissue the transition takes, and it is the tissue a calorie deficit takes too if nothing protects it. The federal guideline puts it in one line: “Muscle-strengthening activities can also help maintain lean body mass during weight loss.” The dose it specifies: “Adults should also do muscle-strengthening activities of moderate or greater intensity and that involve all major muscle groups on 2 or more days a week, as these activities provide additional health benefits.” It also names the honest limit, that muscle-strengthening activities help promote weight maintenance, although not to the same degree as aerobic activity. So strength work is for keeping the tissue, and it is not the lever that moves the scale.
Examples of muscle-strengthening activities include lifting weights, working with resistance bands, doing calisthenics that use body weight for resistance (such as push-ups, pull-ups, and planks), carrying heavy loads, and heavy gardening.
3. Aerobic minutes, at the guideline dose
“For substantial health benefits, adults should do at least 150 minutes (2 hours and 30 minutes) to 300 minutes (5 hours) a week of moderate-intensity, or 75 minutes (1 hour and 15 minutes) to 150 minutes (2 hours and 30 minutes) a week of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate- and vigorous-intensity aerobic activity.” On weight specifically, the same document says “Combining both caloric restriction and physical activity tend to be most beneficial for weight loss rather than just caloric restriction or just physical activity.” and warns that people who want to lose a substantial amount of weight (more than 5 percent of body weight) and people who are trying to keep a significant amount of weight off once it has been lost may need to do more than 300 minutes of moderate-intensity activity a week to meet weight-control goals. Inside PEPI, the trial at the centre of this page, the researchers reported: “After accounting for the effects of assignment to active hormone therapy and baseline weight, older age (P = 0.008) and higher physical activity level at baseline (P = 0.002) were also independently predictive of less weight gain.” Women were randomized to a hormone regimen, not to an activity level, so this is an association observed inside a randomized trial rather than a randomized test of exercise. It is also the finding that survives in a trial designed to test something else, which is usually a good sign.
4. Treat the symptom that is destroying your sleep
This is where hormone therapy legitimately enters, on its own indication rather than a borrowed one. If night sweats are waking you four times a night, that is a treatable vasomotor symptom and it is the thing hormone therapy is approved and recommended for. Whether fixing it moves your weight is unmeasured, as the section above says. Whether it is worth fixing on its own is a different question with a much easier answer.
Federal guideline quotes read on August 16, 2026 from Physical Activity Guidelines for Americans, 2nd edition, US Department of Health and Human Services. Quoted rather than paraphrased on purpose: paraphrase is where “muscle-strengthening activities can help maintain lean body mass during weight loss” becomes “lifting weights burns fat”, which the document does not say.
One thing this page will not do is send you somewhere else for a medicine. If weight is the problem you want treated, that is a different drug class, a different evidence base and a conversation for a clinician who can see your labs. We do not cover it, so we are the wrong people to ask.
FAQ
HRT and weight, answered
Does HRT help with weight loss?
Mostly no, and the randomized record is unusually clear for a menopause question. The Cochrane review of 22 randomized trials found a weighted mean difference of 0.66 kg between unopposed estrogen and no hormone therapy (95% CI -0.62 to 1.93) and -0.47 kg between estrogen plus progestogen and no hormone therapy (95% CI -1.63 to 0.69). Both intervals cross zero, so neither is a statistically significant difference. The most favorable randomized result we found is PEPI, where women assigned to estrogen averaged 1.0 kg less weight gain over three years than women assigned to placebo (P = 0.006). The trial reported that as reduced weight gain and reported no weight loss in any arm. The reviewers' own conclusion reads: "There is evidence of no effect of unopposed oestrogen or combined oestrogen on body weight, indicating that these regimens do not cause extra weight gain in addition to that normally gained at menopause." Hormone therapy is a treatment for the symptoms of estrogen loss, and the estradiol tablet label lists 6 indications with weight on none of them.
Does menopause cause weight gain?
The menopause transition changes body composition. Whether it changes the number on the scale is a separate question and the SWAN cohort answered it in the opposite direction from what most people expect. Fat and lean mass were measured by dual energy x-ray absorptiometry: at the start of the transition the rate of fat gain doubled and lean mass declined, and both continued until two years after the final menstrual period. Weight itself climbed linearly through premenopause with no acceleration at the transition. The authors wrote that there is no discernable change in the rate of weight gain at the start of the transition. So midlife weight gain is real and the transition is not what accelerates it. What the transition accelerates is the swap of lean tissue for fat, which a bathroom scale cannot see.
Why does menopause cause belly fat?
Because the fat redistributes toward the trunk, and the SWAN regional-fat analysis of 380 women measured how fast. Visceral fat began increasing at the transition and rose 6.24 percent a year through it. Android fat, the trunk depot, went from 1.21 percent a year in premenopause to 5.54 percent a year through the transition. Gynoid fat on the hips and thighs rose only 2.03 percent a year and then went negative after menopause. Here is the part that explains why the mirror and the tape measure disagree: waist circumference grew 0.55 percent, 0.96 percent and 0.55 percent a year across the three phases, and the paper reports those three rates are not statistically different from each other. The authors' conclusion is that waist and hip circumferences are less sensitive to changes in fat distribution. The rates given are for the White referent, with significant differences in some trajectories in Black and Japanese women.
Does estrogen help you lose weight?
No randomized trial we found shows estrogen producing weight loss. The FDA-approved label for estradiol tablets lists 6 indications: treatment of moderate to severe vasomotor symptoms associated with the menopause; treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause; treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure; treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease; treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only); prevention of osteoporosis. Weight is on none of them. The only place on that label where weight is treated as something the drug might change is ADVERSE REACTIONS, item 8, Miscellaneous, where the entry reads "Increase or decrease in weight", covering both directions. The word weight appears three other times on this label and none of them describes something the drug does. Twice it is weight-bearing exercise recommended for bone, once in the osteoporosis indication and once in the patient leaflet, and once it is being overweight named as a cardiac risk factor in the patient leaflet. This label lists its adverse reactions by body system with no frequency attached to any of them and no placebo comparison, so it publishes no rate for weight change in either direction. A provider can still offer estrogen to a woman worried about her weight. Nothing on the label supports that use, and prescribing outside the approved list does not create the evidence that would justify it.
Can HRT help with weight loss indirectly?
That is the honest version of the yes, and it is smaller and less proven than the pages selling it suggest. Two links in the chain are supported. A meta-analysis pooling seven trials covering 15,468 women found hormone therapy improved self-reported sleep quality in women who had vasomotor symptoms at baseline, a standardized mean difference of -0.54 (95% CI -0.91 to -0.18), which the authors graded as moderate quality evidence, from trials at a moderate to high risk of bias, and found no difference in women without those symptoms. Separately, a randomized crossover in 10 overweight adults found that cutting sleep opportunity from 8.5 to 5.5 hours during a 14-day calorie deficit reduced the proportion of weight lost as fat by 55 percent and increased the loss of fat-free mass by 60 percent. Three of those ten participants were women and none were described as menopausal. No randomized trial has tested whether treating vasomotor symptoms with hormone therapy produces weight loss through better sleep. The two halves of that chain are each supported and the chain itself has never been measured end to end. Anyone telling you the size of that effect is telling you a number that does not exist.
Does HRT cause weight gain?
The evidence points against it, which is the mirror image of this page's main answer. The same Cochrane review of 22 randomized trials concluded: "There is evidence of no effect of unopposed oestrogen or combined oestrogen on body weight, indicating that these regimens do not cause extra weight gain in addition to that normally gained at menopause." That is a statement about the pooled randomized record rather than about any one product. The label side of the same question, the patch reaction rates read dose by dose with the placebo column and the arm sizes beside them, belongs to our estradiol patch side effects page, which is where those numbers are published with the caveats they need.
What actually works for menopause weight gain?
The Physical Activity Guidelines for Americans, the federal recommendation, is quotable on this and worth reading before any provider's version of it. On combining approaches: "Combining both caloric restriction and physical activity tend to be most beneficial for weight loss rather than just caloric restriction or just physical activity." On the tissue the transition takes: "Muscle-strengthening activities can also help maintain lean body mass during weight loss." It also sets the dose, at least 150 to 300 minutes a week of moderate-intensity aerobic activity, plus muscle-strengthening activities working all major muscle groups on two or more days a week, and it notes that people wanting to lose more than 5 percent of body weight may need more than 300 minutes a week. It adds the caveat most fitness marketing drops, that muscle-strengthening activity promotes weight maintenance although not to the same degree as aerobic activity. Inside PEPI, higher physical activity at baseline independently predicted less weight gain (P = 0.002), though women in that trial were randomized to a hormone regimen rather than to an activity level.
If you came here for hot flashes and stayed for the weight question
Hormone therapy answers the first of those and not the second. If the symptoms are the reason you are here, the highest-scored platform on our women's-wing rankings is Alloy at 8.9/10, $40/mo, Transparency Grade A. The ranking is sorted by score and nobody pays to move on it.
- The full scored rankings all 13women's-wing platforms, score-sorted
- Perimenopause, and what is treatable before periods stop where most of this body-composition change is happening
- Is HRT safe the risk numbers, with their absolute sizes
- Does the estradiol patch cause weight gain the label rates by dose, with the placebo column
- Cheapest verified HRT sorted strictly by price
Sources
Every one of these was opened and read on August 16, 2026. PubMed answers automated clients with a bot challenge rather than the page, so each PMID below was separately confirmed through the NCBI eutils summary service the same day.
- Changes in body composition and weight during the menopause transition, SWAN, JCI Insight 2019 (PMID 30843880)
- Changes in regional fat distribution and anthropometric measures across the menopause transition, SWAN, J Clin Endocrinol Metab 2021 (PMID 34061966)
- Increased visceral fat and decreased energy expenditure during the menopausal transition, Int J Obes 2008 (PMID 18332882)
- Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution, Cochrane Database Syst Rev 2000, CD001018 (PMID 10796730)
- Cochrane plain language summary of CD001018 (The review's own consumer summary, on cochrane.org)
- Effect of postmenopausal hormone therapy on body weight and waist and hip girths, PEPI trial, J Clin Endocrinol Metab 1997 (PMID 9141548)
- Postmenopausal hormone therapy and body composition, a substudy of the estrogen plus progestin trial of the Women's Health Initiative, Am J Clin Nutr 2005 (PMID 16155280)
- Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis, Endocrine 2017 (PMID 27515805)
- Insufficient sleep undermines dietary efforts to reduce adiposity, Ann Intern Med 2010 (PMID 20921542)
- The 2022 hormone therapy position statement of The North American Menopause Society, Menopause 2022 (PMID 35797481)
- Estradiol tablets, USP prescribing information, DailyMed (SPL effective 2026-07-01, read from the structured XML on 2026-08-16)
- Physical Activity Guidelines for Americans, 2nd edition, US Department of Health and Human Services (PDF, read 2026-08-16)
The FDA is named in prose where it is the source of record for an approval or an indication, because www.fda.gov returns a 404 to automated clients and a dead citation is worse than a named one. The label itself is linked through DailyMed, which carries the same text.
This is general information, not medical advice. Hormone therapy is a prescription treatment and whether you need it, in which form, at which dose, is a decision for you and a licensed clinician. Nothing here is a weight-loss recommendation, and no page can replace an examination and your own labs. Reviewed by Iacob Pastina.
Midi Health
Sesame Care